← All trials
NCT04705714
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2021
- Primary completion
- Mar 1, 2021
- Completion date
- Mar 1, 2021
- First posted
- Jan 12, 2021
- Last posted
- Jul 22, 2021
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tanta UniversityLead sponsor
- Tanta UniversityReponsible party - principal investigator
- Tanta UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.